Danaher Corporation -- Financial Trends

6 / 10

Financial Trends  ·  Weight: 25%

Post-COVID bioprocessing destocking recovery is genuine and broadening. The trough of -7.5% core growth in Q1 2024 reflected the sharp unwind of pandemic-era over-ordering by biologic manufacturers. As customer inventory levels normalized through 2024, order books recovered: management noted six consecutive quarters of high-single-digit sequential order growth by Q4 2024. By Q3 2025, core growth reached +3.0%, led by Biotechnology (Cytiva), with Life Sciences recovering more gradually and Diagnostics growing outside of China VBP headwinds. Q4 2025 came in at +2.5%, slightly below the Q3 peak, but management confirmed a strong finish across the portfolio. FY2026 guidance of 3% to 6% core growth reflects continued bioprocessing equipment recovery layering onto durable consumables momentum.

Revenue returned to growth in FY2025 after two flat years. After the bioprocessing destocking cycle held FY2023 revenue at $23.89B (-0.5%) and FY2024 at $23.88B (essentially flat), FY2025 recovered to $24.57B (+2.9%), reaching a new high. The FY2022 peak of $24.0B was exceeded for the first time. Management guided FY2026 revenue of approximately $25.89B (+5.4%), with consensus estimates reaching $27.47B by FY2027E (+6.1%). The multi-year revenue CAGR from FY2021 to FY2027E would be approximately 4.7%, in line with the company's long-term target of mid-single-digit core growth.

Biotechnology leads the recovery; Life Sciences flat; Diagnostics steady. Biotechnology (Cytiva bioprocessing) was the standout in FY2025, recovering +8.0% after a -5.8% decline in FY2024. The recovery is driven by consumables volumes returning to normal utilization, with equipment orders following as customers expand capacity. Life Sciences grew just +0.1% in FY2025 (flat), reflecting continued softness in academic and biopharma capital spending. Diagnostics grew +1.6% despite China VBP headwinds, supported by Cepheid respiratory strength and Beckman Coulter's mid-single-digit growth outside China. Biotechnology now represents approximately 30% of total revenue and carries the highest operating margins in the portfolio.

~340bps compression from peak reflects deliberate investment choices, not structural deterioration. Adjusted operating margin declined from 31.5% (FY2021) to 28.2% (FY2025), a compression of approximately 340bps over four years. The primary drivers are: (1) integration of Cytiva (2020), Abcam (2023), IDT and Aldevron -- all acquired at dilutive operating margins relative to legacy Danaher; (2) approximately $175M+ of productivity investments in FY2025 that DHR does not add back to adjusted earnings (unusual versus peers); and (3) China VBP headwinds in the Diagnostics segment compressing blended margins.

Management guided greater than 100bps of adj. operating margin expansion in FY2026, supported by approximately $250M in net restructuring savings (approximately $0.30 EPS tailwind). Q1 2026 guidance of approximately 28.5% adj. OP margin was set as a floor with acceleration expected through the year. Q4 2025 adj. OP margin of 28.3% was down 130bps YoY, partly due to in-period productivity investment timing -- this is the key reason for the -1 point penalty in the score.

V-shape recovery underway: trough $7.48 (FY2024) to recovery path toward prior peak. Adj. EPS peaked at $11.80 in FY2022 during the COVID biologics boom, then declined steeply to $9.71 (FY2023, -17.7%) and $7.48 (FY2024, -23.0%) as bioprocessing destocking played out. FY2025 marked the first year of growth: $7.80 (+4.3%), with management beating the upper end of the initial guide of $7.60 to $7.75. FY2026 guidance is $8.35 to $8.50 (midpoint ~$8.42, +7.9% growth), supported by $250M restructuring savings, bioprocessing volume leverage, and approximately 5 to 10M fewer diluted shares from continued buybacks.

FY2027E consensus of $9.21 (+9.4%) would represent approximately 78% recovery toward the FY2022 peak, with FY2028 to FY2029 potentially reclaiming prior highs if bioprocessing equipment demand normalizes fully and margin expansion materializes as guided.

34 consecutive years of greater than 100% FCF/NI conversion: an exceptional quality signal. FCF declined from $7.5B (FY2022) to $5.3B (FY2023) as the bioprocessing cycle unwound and then held flat at $5.3B through FY2024 and FY2025. While flat in dollar terms, this stability is notable: DHR invested approximately $250M in restructuring and productivity improvements during FY2025 without adding these back to adjusted earnings -- most peers would have adjusted these out, artificially inflating reported FCF. On a normalized basis, FCF is slightly growing.

FCF/NI conversion was approximately 135% in FY2024 and approximately 145% in FY2025, reflecting strong working capital management and minimal maintenance capex requirements relative to depreciation. Q4 2025 FCF of $1.8B (+20% YoY) was the strongest quarterly FCF result in recent history and signals the beginning of FCF dollar growth. FY2026 FCF is expected to grow as operating leverage drives margin expansion and restructuring capex stabilizes.

No dilution penalty: share count is clearly and consistently declining. Diluted shares declined from approximately 746M in Q1 2024 to approximately 706M in Q4 2025, a reduction of approximately 40M shares or 5.4% in the trailing eight quarters. From peak levels near 782M shares in early 2023, the total reduction is approximately 76M shares (~9.7%) over three years. Management deployed approximately $7B in buybacks across FY2024 and FY2025, with approximately $2B deployed in Q3 2025 alone (approximately 10M shares).

A new 35M share repurchase authorization was approved in Q3 2025, providing capacity for continued buybacks. YoY share reductions of -3.8% in Q1 and Q2 2025 moderated to -2.2% in Q4 2025, partly because buyback pace was somewhat higher in early 2025. Management maintains a primary M&A bias but will buy back shares opportunistically when relative value is attractive. Continuing buybacks in FY2026 of $1B to $2B annually would reduce shares by a further 5M to 10M, providing additional EPS tailwind.

Positive factors (supporting 6/10 vs. mid-point of 5):

• Revenue trajectory is accelerating: from -7.5% core trough (Q1 2024) to +2.5% to 3.0% (Q3 to Q4 2025) -- directionally correct with management guiding 3% to 6% core growth in FY2026.
• Share count unambiguously declining: approximately 9.7% reduction over three years, no dilution penalty, active buyback program with new authorization approved Q3 2025.
• FCF positive and exceptionally durable: $5.3B annually with 34 consecutive years of greater than 100% FCF/NI conversion -- best-in-class capital efficiency in life science tools.
• Adj. EPS growing +4.3% in FY2025, with management guiding +7.9% in FY2026; V-shape recovery is underway and trajectory is improving quarter by quarter.
• Dominant market positions with regulatory moat: Cytiva is global #1 in bioprocessing consumables; Cepheid is #1 in point-of-care molecular diagnostics.

Offsetting factors (capping score below 7):

• Adj. operating margin compressed approximately 340bps from peak (31.5% to 28.2%), reflecting acquisition integration costs and productivity investments. Margin has not yet demonstrated the promised recovery.
• FCF flat in dollar terms over FY2024 to FY2025 ($5.3B each year): not growing despite revenue recovery, reflecting $250M+ of non-adjusted restructuring costs absorbed in-period.
• FY2023 guidance miss was significant (initial guidance for modest growth; actual core revenue declined approximately 6%) -- the 3-year track record includes one material miss, though caused by industry-wide forces.

Penalty applied: -1 point
Revenue growing (+4.7% YoY in Q4 2025) but adjusted operating margin contracted 130bps in Q4 2025. For the full year FY2025, revenue grew +2.9% while adj. OP margin fell -40bps vs. FY2024. This revenue growth / margin compression divergence triggers the standard -1 penalty. To achieve a 7/10, FY2026 must deliver on the promised greater than 100bps margin expansion alongside continued revenue growth.